期刊
BIOMATERIALS
卷 35, 期 7, 页码 2374-2382出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2013.11.076
关键词
Glioblastoma; Antiangiogenesis; Anti-tumor therapy; Dual targeting delivery
资金
- National Basic Research Program of China [2013CB932502]
- National Science and Technology Major Project [2012ZX09304004]
- Department of Health of Zhejiang Province [2013KYA134]
Glioblastoma multiforme (GBM), one of the most common primary malignant brain tumors, was characterized by angiogenesis and tumor cells proliferation. Antiangiogenesis and antitumor combination treatment gained much attention because of the potency in dual inhibition of both the tumor proliferation and the tumor invasion. In this study, a neovasculature and tumor cell dual targeting delivery system was developed through modification of nanoparticles with interleukin-13 peptide and RGD (IRNPs), in which interleukin-13 peptide was targeting GBM cells and RGD was targeting neovasculature. To evaluate the potency in GBM treatment, docetaxel was loaded into IRNPs. In vitro, interleukin-13 peptide and RGD could enhance the corresponding cells (C6 and human umbilical vein endothelial cells) uptake and cytotoxicity. In combination, IRNPs showed high uptake in both cells and increased the cytotoxicity on both cells. In vivo, IRNPs could effectively deliver cargoes to GBM with higher intensity than mono-modified nanoparticles. Correspondingly, docetaxel-IRNPs displayed best anti-tumor effect with a median survival time of 35 days, which was significantly longer than that of mono-modified and unmodified nanopartides. Importantly, treatment with docetaxel-IRNPs could avoid the accumulation of HIFI alpha in GBM site, which was crucial for the tumor invasion. After the treatment, there was no obvious change in normal organs of mice. (c) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据